Inter-assay variability in anti–JC virus serology in the era of natalizumab biosimilars: implications for PML risk stratification
Anti–John Cunningham virus (JCV) serological testing constitutes a cornerstone of progressive multifocal leukoencephalopathy (PML) risk assessment in patients receiving natalizumab for multiple sclerosis (MS). Existing PML risk stratification algorithm…